James Tarbox, MD
Allergy & Immunology · Lubbock, TXNPI 1700063591
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by CSL Behring at 55.1% of the total. 2025 is the largest year on record at $8,161, 7.7 times the $1,057 reported in 2019.
Across 164 payments — averaging $74.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$7K
- AstraZeneca$1K
- GSK$919
- Amgen$868
- Regeneron Healthcare Solutions, Inc.$440
- Sanofi$347
- plus $2K from 18 others
What the payments were for
- Consulting fees$5,75247%
- Travel & lodging$7406%
- Food & beverage$5,65346%
- Education$891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 8 | $6,736 |
| AstraZeneca | 21 | $1,087 |
| GSK | 28 | $919 |
| Amgen(2 entities) | 46 | $868 |
| Regeneron Healthcare Solutions, Inc. | 10 | $440 |
| Sanofi | 5 | $347 |
| Genentech USA, Inc. | 11 | $272 |
| Boehringer Ingelheim | 3 | $236 |
| Lilly USA, LLC | 2 | $204 |
| Novartis | 9 | $181 |
| AbbVie(2 entities) | 4 | $156 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $115 |
| Blueprint Medicines Corporation | 1 | $98 |
| Intuitive Surgical | 1 | $97 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Ionis Pharmaceuticals, Inc. | 2 | $69 |
| Biocryst US Sales Co., LLC | 3 | $62 |
| Teva Pharmaceuticals USA, Inc. | 1 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Insmed, Inc. | 1 | $27 |
| Catalyst Pharmaceuticals, Inc. | 1 | $21 |
| Merck | 1 | $14 |
| Mylan Specialty L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,234 in reported general payments places this provider in the 70th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 13 | $83,766 |
| TezspireTezepelumab-Ekko | 18 | $79,278 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,822 |
| Ipratropium Bromide | 64 | $1,319 |
| Azelastine Hcl | 34 | $1,093 |
| Olopatadine Hcl | 25 | $1,066 |
| Epinastine Hcl | 11 | $736 |
| Fluticasone Propionate | 35 | $658 |
| Montelukast Sodium | 55 | $425 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $371 |
| Prednisone | 24 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire | $1,087 | $79,27818 claims |
| GSKBreo Ellipta | $919 | $6,82214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Lubbock
- Goutam ShomeLubbock$26K
- Joseph DiazSan Antonio$1.1M
- Richard WassermanDallas$452K
- Matthew FeldmanDallas$410K
- Lukena KarkhanisSan Antonio$377K
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
- Lara GrossDallas$171K
- Bobby LanierBenbrook$149K
- Juan ZambranoHouston$146K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.